Non small cell lung cancer with SMARCA4 deficiency harboring rare EGFR mutations exhibited significant tumor response when treated with afatinib: a case report.
10.1007/s11684-024-1118-y
- Author:
Xiaotong QIU
1
;
Liangkun YOU
1
;
Chongwei WANG
2
;
Jin SHENG
3
Author Information
1. Department of Medical Oncology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, 310016, China.
2. Department of Pathology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, 310016, China. cadillac_luck@zju.edu.cn.
3. Department of Medical Oncology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, 310016, China. shengjin@zju.edu.cn.
- Publication Type:Case Reports
- Keywords:
SMARCA4-dNSCLC;
case report;
rare EGFR mutations;
targeted therapy
- MeSH:
Humans;
Afatinib/therapeutic use*;
Antineoplastic Agents/therapeutic use*;
Carcinoma, Non-Small-Cell Lung/pathology*;
DNA Helicases/genetics*;
ErbB Receptors/genetics*;
Lung Neoplasms/pathology*;
Mutation;
Nuclear Proteins/genetics*;
Transcription Factors/genetics*
- From:
Frontiers of Medicine
2025;19(1):170-173
- CountryChina
- Language:English
-
Abstract:
SMARCA4-deficient non small cell lung cancer (SMARCA4-dNSCLC) has recently garnered increasing attention due to its high malignancy and poor prognosis. The literature suggests that in non small cell lung cancer (NSCLC), the loss of SMARCA4 frequently co-occurs with mutations in KRAS, KEAP1, and STK11 rather than in EGFR, ALK, and ROS1. Herein, we present the first documented case of SMARCA4-dNSCLC accompanied with rare mutations of EGFR exon 20 S768I and exon 18 G719X. The patient achieved partial response with afatinib for 17 months. Our case highlights the importance of EGFR mutations in the precision targeted treatment of SMARCA4-dNSCLC.
